Doer Bio Completes Enrollment in Phase 1b/2a Trial of DR10624

Doer Bio Completes Enrollment in Phase 1b/2a Trial of DR10624

By, Admin 8 July 2024

Doer Bio completes enrollment in phase 1b/2a trial of DR10624 in obese subjects with modest hypertriglyceridemia

Overview

Zhejiang Doer Biologics Co., Ltd. (Doer Bio), a clinical stage biopharmaceutical company, announces that the company has completed the enrollment in the phase 1b/2a trial evaluating DR10624 in obese subjects with modest hypertriglyceridemia in New Zealand. DR10624 is a first-in-class (FIC), long-acting tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR).

Phase 1b/2a Study

  • The phase 1b/2a study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DR10624 in adult obese subjects (BMI of 30 to 45 kg/m2) with modest hypertriglyceridemia (fasting triglyceride =150 mg/dL (1.7 mmol/L), and <500 mg/dL (5.7 mmol/L), at screening). 
  • The study evaluates DR10624 treatment across four different dose levels. 
  • The participants will receive once-weekly subcutaneous injection of DR10624 or placebo (in a 10:2 ratio) for 12 weeks.
  • The study will also evaluate the effects of DR10624 on serum lipids, liver fat, and body weight.

Words of CEO: Doer Bio

DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing FGF21R, GLP-1R, and GCGR. Utilizing Doer Bio's proprietary MultipleBody platform technology, DR10624 is designed and engineered to exhibit balanced activity for various metabolic diseases. In our preclinical studies, DR10624 has shown outstanding potency on body weight reduction, blood lipid normalization, and liver function improvement."" said Yanshan Huang, Ph.D., founder and chief executive officer of Doer Bio.

Words from COO: Doer Bio

We're excited to announce the successful completion of patient enrollment for our phase 1b/2a clinical trial of DR10624 in New Zealand. This achievement marks an important milestone in our clinical translation of DR10624 globally. We anticipate reporting the trial results in early 2025. There is a growing unmet medical need for patients suffering from obesity and hypertriglyceridemia. We look forward to developing DR10624 as a potential treatment for patients struggling with metabolic dysfunction."" commented Yongliang Fang, Ph.D., chief operating officer of Doer Bio.

Zhejiang Doer Biologics Co.

Zhejiang Doer Biologics Co., Ltd. (Doer Bio) is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!